TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22611313
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplementation (32 g/d for 12 weeks)
Study: 22611313
Drug: Casein supplementation
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein supplementation (control group, 32 g/d for 12 weeks)
Study: 8857632
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (NTG) 5-mg patch per day over 3 days
Study: 3330182
Drug: Sublingual prazepam
Normalized name: prazepam
DrugBank: Prazepam (DB01588)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual prazepam
Study: 3330182
Drug: Oral prazepam
Normalized name: prazepam
DrugBank: Prazepam (DB01588)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prazepam
Study: 27716293
Drug: TNT009, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNT009, a humanized monoclonal antibody directed against the C1s subunit of human complement component C1, administered in a double-blind, randomized, placebo-controlled manner.
Study: 22882646
Drug: Metronidazole (MTZ)
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole (MTZ) 400 mg/TID and Amoxicillin (AMX) 500 mg/TID for 14 days
Study: 20073214
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy with Premarin 0.625 g, once daily by oral taking
Study: 8182900
Drug: Fluconazole (FLCZ)
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole (FLCZ) administered intravenously at a dosage of 3 mg/kg
Study: 8182900
Drug: Fluconazole (FLCZ)
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole (FLCZ) administered orally
Study: 8182900
Drug: Fluconazole (FLCZ)
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole (FLCZ) administered intravenously
Study: 3235820
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) at several doses
Study: 26558293
Drug: Stem cell
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cell therapy (mesenchymal stem cells and neural fetal stem cells)
Study: 23725917
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (600 mg daily)
Study: 20642205
Drug: 1.5% bepotastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% bepotastine besilate ophthalmic solution
Study: 18377661
Drug: Cissus quadrangularis/Irvingia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cissus quadrangularis/Irvingia gabonensis combination
Study: 31025274
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (anti-PD-1 and anti-CXCR4)
Study: 24504098
Drug: Aganirsen (0.86
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aganirsen (0.86 mg/g)
Study: 24504098
Drug: Aganirsen (1.72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aganirsen (1.72 mg/g)
Study: 22873635
Drug: In sequence
Approvals — FDA: no, EMA: no, PMDA: no
Description: In sequence computer tutorial (e.g. FWS patient + FWS tutorial)
Study: 22873635
Drug: Out-of-sequence computer
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-of-sequence computer tutorial (e.g. FWS patient + ORS tutorial)
Study: 17118996
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg iodine as oral iodized oil
Study: 17118996
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg iodine as oral iodized oil (two doses)
Study: 12164886
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (optimal doses of lisinopril and losartan)
Study: 10204938
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of morphine (1 ml) and 9 ml of saline
Study: 10204938
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of bupivacaine (2.5 mg/ml)
Study: 10204938
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of morphine (1 ml) and 9 ml of bupivacaine (2.5 mg/ml)
Study: 2155948
Drug: conventional metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional metoprolol 100 mg
Study: 7006073
Drug: Vaccinated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated with intact influenza vaccine
Study: 27406943
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of enteral nutrition formulas (2 different formulas)
Study: 27406943
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g lactulose
Study: 21516022
Drug: IV anti-D
Normalized name: anti-D (rh) immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV anti-D (50 μg/kg)
Study: 21516022
Drug: IVIG (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (0.8 to 1 g/kg)
Study: 19920236
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d)
Study: 16972106
Drug: d-amphetamine 0
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 0 mg/70 kg (placebo)
Study: 14740785
Drug: Intranasal hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal hydromorphone hydrochloride after 6 days of fluticasone propionate (treatment C)
Study: 14740785
Drug: Intranasal hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal hydromorphone hydrochloride without allergic rhinitis treatment (treatment B)
Study: 14740785
Drug: Intravenous hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydromorphone hydrochloride 2.0 mg (treatment A)
Study: 14740785
Drug: Intranasal treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal treatments (B and C)
Study: 14740785
Drug: Intranasal hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal hydromorphone hydrochloride
Study: 3010011
Drug: Oral nabilone
Normalized name: Nabilone
DrugBank: Nabilone (DB00486)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nabilone (1 mg 8 hourly)
Study: 3010011
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (1 mg kg‐1 3 hourly)
Study: 24901089
Drug: SDF (oat
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDF (oat β‐glucan 7.5 g, 500 mL, 500 Kcal)
Study: 22830971
Drug: Milled chia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milled chia seed (25 g/day for 10 weeks)
Study: 22830971
Drug: Whole chia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole chia seed (25 g/day for 10 weeks)
Study: 22830971
Drug: Placebo (poppy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (poppy seed, 25 g/day for 10 weeks)
Study: 17461474
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg twice daily) and Domperidone (10 mg three times daily)
Study: 16036039
Drug: Statins (3‐Hydroxy‐3‐methylglutaryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (3‐Hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors)
Study: 12113287
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day alpha-tocopherol supplementation
Study: 2800995
Drug: Ketamine 10
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 10 mg.kg‐1 BW and midazolam 0.2 mg.kg‐1 BW for induction with intravenous ketamine for maintenance
Study: 2800995
Drug: Ketamine 10
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 10 mg.kg‐1 BW and midazolam 0.2 mg.kg‐1 BW for induction with halothane for maintenance
Study: 30796528
Drug: Stepped Collaborative
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepped Collaborative Care Model (SCCM) including group-level interventions (START intervention, Empowerment/Gender-sensitive/Peer to peer) and digital treatment approaches (Smartphone application)
Study: 29199566
Drug: High-dose supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose supplement (HD) group
Study: 29199566
Drug: Low-dose supplement
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose supplement (LD) group
Study: 22276649
Drug: Conventional resin-based
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional resin-based sealant with Er:YAG + AE preparation technique
Study: 21190996
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (HiDAC, 2 g/m(2) twice daily for 5 days)
Study: 21190996
Drug: Multiagent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiagent chemotherapy (CT)
Study: 21190996
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (HiDAC)
Study: 16110019
Drug: CI-1033 200
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-1033 200 mg daily for 21 days in a 28-day cycle
Study: 16110019
Drug: CI-1033 50
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-1033 50 mg daily for 21 days in a 28-day cycle
Study: 11932085
Drug: Intravenous meperidine/diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine/diazepam (IVMD)
Study: 8553820
Drug: metallic implants
Normalized name: Aluminum metal
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: metallic implants
Study: 25041333
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (LTPP + fluoxetine)
Study: 25041333
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment (20‐60 mg/day)
Study: 23733915
Drug: High free
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High free fatty acid (FFA) levels (intralipid/heparin-infusion)
Study: 15083317
Drug: Soy cookies
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy cookies (52 mg isoflavones)
Study: 9806658
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose megestrol acetate (160 mg/day)
Study: 9806658
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose megestrol acetate (640 mg/day)
Study: 8543705
Drug: Cognitive-behavioral relapse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral relapse prevention treatment
Study: 2622988
Drug: Ethanol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.75 g/kg) after sleep extension
Study: 402406
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium nasal solution (4% aqueous solution)
Study: 31369675
Drug: Cervical headgear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical headgear treatment (CH) started at age 7.8 years (Early Group - EG)
Study: 31369675
Drug: Cervical headgear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical headgear treatment (CH) started at age 9.5 years (Late Group - LG)
Study: 28894768
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid + 3% hypertonic solution
Study: 28894768
Drug: 3% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hypertonic solution
Study: 17942782
Drug: Sodium ferric
Normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferric gluconate complex (1.5 mg/kg)
Study: 17942782
Drug: Sodium ferric
Normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferric gluconate complex (3.0 mg/kg)
Study: 29969293
Drug: G‐CBT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CBT + ABM
Study: 29969293
Drug: G‐CBT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CBT + ACT
Study: 27275618
Drug: Osseointegrated implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osseointegrated implants subjected to 200-cN force
Study: 27275618
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (implants not subjected to orthodontic force)
Study: 20216276
Drug: Mediterranean diet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet, physical exercise, and daily oral ingestion of 40 mg of soy isoflavones
Study: 17711562
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g intravenous paracetamol
Study: 12966366
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg diclofenac
Study: 14551147
Drug: Second-generation oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-generation oral contraceptive (30 microg ethinylestradiol/150 microg levonorgestrel)
Study: 14551147
Drug: Third-generation oral
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Third-generation oral contraceptive (30 microg ethinylestradiol/150 microg desogestrel)
Study: 12138364
Drug: Progestagen-only preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestagen-only preparation (150 microg levonorgestrel)
Study: 12138364
Drug: Progestagen-only preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestagen-only preparation (150 microg desogestrel)
Study: 9527763
Drug: Indinavir at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir at 1,000 mg every 8 h for 7 1/3 days with fluconazole placebo
Study: 9527763
Drug: Fluconazole at
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole at 400 mg once daily for 8 days with indinavir placebo
Study: 9527763
Drug: Indinavir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir with fluconazole in combination
Study: 7599543
Drug: Methadone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone at 0.30 mg/kg
Study: 7599543
Drug: Morphine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine at 0.30 mg/kg
Study: 2090769
Drug: mezlocillin 2
Normalized name: mezlocillin 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: mezlocillin 2 g i.v. 15 to 20 minutes preoperatively
Study: 2090769
Drug: cefotetan 2
Normalized name: cefotetan 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefotetan 2 g i.v. 15 to 20 minutes preoperatively
Study: 359091
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate dry powder 150 microgram four times daily
Study: 359091
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate dry powder 100 microgram four times daily
Study: 359091
Drug: Conventional aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional aerosol 100 microgram four times daily
Study: 26892074
Drug: Recipe booklet
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recipe booklet and monthly reminder text messages
Study: 20661550
Drug: Dopamine D2/D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2/D3 receptor agonist (pramipexole)
Study: 20661550
Drug: Dopamine D2/D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2/D3 receptor antagonist (amisulpride)
Study: 15831781
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 µg) injected subcutaneously at 0 hours with acetaminophen (1000 mg) ingested at -1, 0, +1, +2, and +4 hours.
Study: 15831781
Drug: Placebo injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected subcutaneously at 0 hours with acetaminophen (1000 mg) ingested.
Study: 16492988
Drug: Prebiotic-supplemented milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic-supplemented milk formula (4.5 g/L)
Study: 24299553
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC) containing 30 μg ethinyl estradiol and 3 mg drospirenone (group I; n = 21)
Study: 15975313
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with leeching intervention, n = 24
Study: 29027235
Drug: Commercially reconstructed
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially reconstructed quarter-dose images with no noise reduction
Study: 29027235
Drug: Full-dose commercial
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose commercial images
Study: 17546902
Drug: Sulfadoxine/pyrimethamine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine/pyrimethamine monotherapy
Study: 17546902
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Chloroquine + Sulfadoxine/pyrimethamine)
Study: 11686428
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg inhaled plus 200 microg intranasal budesonide once daily
Study: 11686428
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg montelukast plus 10 mg cetirizine once daily
Study: 9307671
Drug: Calcium-channel antagonists
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-channel antagonists
Study: 16284750
Drug: Amphetamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine administration
Study: 3145528
Drug: Saline (control)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (control) administration
Study: 26092818
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg once daily) plus trastuzumab and paclitaxel
Study: 9285305
Drug: 5 alpha-reductase
Normalized name: 5.alpha.-hydroxy laxogenin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 alpha-reductase inhibitor (finasteride 5 mg/day)
Study: 7687111
Drug: PRP-OMPC vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-OMPC vaccine
Study: 3828185
Drug: Extradural phenoperidine
Normalized name: phenoperidine
DrugBank: Phenoperidine (DB13605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural phenoperidine 2 mg
Study: 3828185
Drug: Extradural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural diamorphine 5 mg
Study: 3828185
Drug: i.m. diamorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. diamorphine 5 mg
Study: 26236130
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (DFDBA and barrier membrane)
Study: 26236130
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment + doxycycline group (DFDBA and barrier membrane with local doxycycline)
Study: 23332533
Drug: Self-monitoring (SM)
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-monitoring (SM) intervention, daily dietary logs for 6 weeks
Study: 21700946
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MI) - 4 individual, weekly sessions
Study: 16703253
Drug: Laser acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser acupuncture (5 mW HeNe laser on 22 acupuncture points for 15 s each) plus cervical collar and a combination of paracetamol and chlormezanone
Study: 16703253
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser treatment plus cervical collar and a combination of paracetamol and chlormezanone
Study: 15319718
Drug: Oxandrolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (10 mg po BID)
Study: 73912
Drug: Polyglycolic acid
Normalized name: polyglycolic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyglycolic acid (P.G.A.) suture material
Study: 26569658
Drug: Ribavirin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (in combination with Sofosbuvir and Velpatasvir)
Study: 23593314
Drug: Investigator selected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator selected boosted comparator HIV-1 protease inhibitors (CPI-Ritonavir)
Study: 16920858
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (30 mg daily for 6 months)
Study: 16920858
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg daily for 6 months)
Study: 12943174
Drug: Kyuki‐chouketsu‐in at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kyuki‐chouketsu‐in at a dose of 6.0 g/day (Group K)
Study: 17436360
Drug: Ergometrine (methylergometrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergometrine (methylergometrine maleate) at a dose of 0.375 mg/day (Group E)
Study: 10848853
Drug: Aprotinin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (2 x 10^6 units bolus, followed by 0.5 x 10^6 units infusion every 30 min)
Study: 7034929
Drug: High-dose MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MTX
Study: 9332684
Drug: Moderate-dose MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose MTX
Study: 9332684
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with MTX and CDP